Specifically, ARID1A amplifications occurred in 67% of cases, making it one of the most common mutations in patients with bladder cancer.[12] Our samples also exhibited some common genomic mutations reported in bladder cancer,[13] such as SLX4, MTAP, SPEN, and SDHC. This evidence concerns the gene ARID1A and urinary bladder cancer.